Leading the Way in Diabetes Care and Research

Hoag is committed to being at the forefront of trusted, tested and new methods of helping patients take control of their diabetes care.

That’s why Hoag is fast to incorporate new tools like the first FDA-approved insulin pen - helping people better manage their blood sugar through the CUPID clinical trial, and the world’s first FDA-approved long-term implantable glucose sensor – the Eversense® Continuous Glucose Monitoring (CGM) System.

While the smart pen and sensor are new, the ability to receive cutting-edge technology at the Mary & Dick Allen Diabetes Center at Hoag is not.

The center opened 10 years ago with a promise to the community to provide dedicated, advanced care in a welcoming environment. Today, Hoag continues to honor that commitment by placing a strong emphasis on research and technology as the cornerstones of diabetes care.

“When the Center opened, the idea was to provide access to the latest research in prevention, monitoring and management of diabetes. What has emerged over the past decade is a center that is truly paving the way of the future of diabetes care,” said Kris V. Iyer, senior vice president, chief administrative office, HMTS.

The Allen Diabetes Center maintains a strong clinical and psychosocial research program with a primary objective of improving the lives of people with diabetes. At Hoag, patients have the opportunity to participate in the latest trials, such as the CUPID study, conducted by Dr. David Ahn, program director, to test the effectiveness of a new smartphone-connected pen in diabetes management.

“With new technologies, we can partner with our patients to help identify the best ways to meet their long-term treatment goals,” said Dr. Ahn. “We are committed to innovating because we see firsthand how these evolving technologies change the way we deliver care and improve the quality of life for our patients.”

For example, Eversense is the latest in continuous glucose monitoring (CGM) systems, which all but eliminate the need for patients to stick their fingers multiple times a day to monitor glucose levels. Hoag offers several types of systems, to allow patients to make their own choices about which product is right for them.

“By continuously monitoring glucose levels, these devices provide the equivalent of 300 finger-sticks’ worth of information a day,” Dr. Ahn said. “It’s like reliving an event through video rather than through photographs. The amount of information provided by this new technology renders the older technology incomplete.”

Dr. Iyer said, “The fact that our patients have access to clinical trials and leading technologies, while still enjoying our community-based hospital approach, is a significant indicator of how far we’ve come and how far we plan to go.”

In addition to offering new devices and clinical trials, Hoag is at the forefront of behavioral research and psychosocial support services for patients and their families.

Under the leadership of psychologist Harsimran Singh, PhD, the outcomes of these research studies will be instrumental in developing person-centered interventions to assist patients and their families better manage diabetes and improve their quality of life.

Dr. Singh is involved in a number of behavioral trials focusing on patient reported psychosocial aspects of diabetes and is currently spearheading a research study to improve the understanding of transition of care from pediatric to adult care for patients with type 1 diabetes.

This national study involves adults with type 1, their parents, and health care providers and the results are expected to support implementation of patient-centered transition of care processes.

Patients interested in clinical or behavioral research trials may visit the Diabetes Clinical Trials page to learn more about the available studies and criteria or email the Allen Diabetes Center research team at [email protected].